NCT05085197已完成1 期
A Phase I, Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STSA-1005 Following Intravenous Infusion in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Incidence of Adverse Events, Serious Adverse Events, Clinically Significant Laboratory Abnormalities, Electrocardiogram Abnormalities, Vital Signs Abnormalities and Physical Examination Abnormalities.
研究概览
简要总结
This was a single ascending dose, randomized, double-blind study assessing the safety, tolerability and pharmacokinetics of STSA-1005 in healthy participants. Four kinds different doses and dose-matched placebo were administered under fasted conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects are able to understand and are willing to sign the informed consent form (ICF).
- •Subjects (male or female) must be ≥18 to ≤65years of age inclusive.
- •Healthy subjects according to the results of medical history, physical examination, vital signs, ECG, and clinical laboratory examination. The Investigator considers that the subjects are in good health with no clinically significant heart, liver, kidney, digestive tract, nervous system, respiratory system, mental disorders, and metabolic disorders.
- •Subjects with a body mass index (BMI) of 20-32kg/m^2, inclusive.
- •(1)If a subject is a female of childbearing potential - she should agree to use one of the accepted contraceptive regimens from at least 30 days before screening, during the study, and for at least 3 months after administration of the study treatment.1)An acceptable method of contraception includes one of the following:
- •Abstinence from heterosexual intercourse;
- •Hormonal contraceptives (birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch);
- •Intrauterine device (with or without hormones). 2)OR she should agree to use a double-barrier method (e.g., condom and spermicide) during the study and for at least 3 months after administration of the study treatment.
- •(2)If a subject is a female of non-childbearing potential - she should be surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation/occlusion) or in a menopausal state (at least 1 year without menses), as confirmed by Follicle stimulating hormone (FSH) levels (≥40 mIU/mL).
- •A male study subject that engages in sexual activity that has the risk of pregnancy must agree to use a double-barrier method (e.g., condom and spermicide) and agree to not donate sperm during the study and for at least 90 days after administration of the study treatment.
- •Subjects understand the risks of the study, can comply with the study protocol, and complete the study.
排除标准
- •History of cardiovascular, respiratory, kidney, liver, metabolic, endocrine, gastrointestinal, blood, neurological, skin, psychiatric, cancer, or other major serious diseases that in the judgment of the Investigator might put the subject at risk on this study.
- •History of tuberculosis (active or latent) irrespective of treatment status or infection within the past 4 weeks or history of recurrent infections.
- •History of or current active autoimmune disease or immunodeficiency disease.
- •Subjects who have a history of clinically significant drug allergy or atopic allergic disease or known allergic reaction or hypersensitivity to the study treatment or its excipients according to the judgment of the Investigator.
- •Subjects who have a history of drug abuse in the 12 months before screening or who have a positive urine drug tests at the time of screening.
- •Subjects who have taken biologic agents within 3 months or 5 times the half-life (whichever is longer) before screening, or who have taken drugs that may affect immune function within 6 months or 5 times the half-life (whichever is longer) before screening, or over-the-counter (OTC) medications (including herbal medicines such as St John's Wort, homoeopathic preparations, vitamins, and minerals) within 7 days prior to IMP administration.
- •Subjects who have received treatment with an investigational drug within 30 days or 5 times the half-life (whichever is longer) prior to screening or 90 days for biologic compounds prior to screening.
- •Blood donation (excluding plasma donation) of approximately 500 mL within 56days before screening or plasma donation within 7 days before screening.
- •Those whose daily consumption of alcohol at the time of screening or at any time within the prior 6 months is more than 2 standard drinks, where 1 standard drink = 355 mL or 12 oz (1can) of regular-strength (5%) beer; 150 mL or 5 oz wine; 45 mL or 1.5 oz liquor/spirits (40%) or who are positive for alcohol tests during the screening period.
- •Female subjects who are breastfeeding or pregnant or who have positive serum pregnancy test during the screening period and on admission.
- •Subjects who have difficulty in venous blood collection or who exhibits risk of fainting after blood collections or with the site of needles.
- •Human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody test results are positive during the screening period.
- •Any acute or chronic condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study.
- •Subjects who have participated in any vaccine clinical study as subjects within 3 months before enrollment or plan to receive live vaccines during the study period, and subjects who have received inactivated vaccines 28 days prior to the IMP administration or plan to receive inactivated vaccines within 2 months after the end of the study.
研究组 & 干预措施
Cohort 1:1mg/kg
Experimental
All participants (fasted) received either 1mg/kg of STSA-1005 as a single dose or dose-matched placebo.
干预措施: STSA-1005 injection (Drug)
Cohort 1:1mg/kg
Experimental
All participants (fasted) received either 1mg/kg of STSA-1005 as a single dose or dose-matched placebo.
干预措施: Placebo (Drug)
Cohort 2:2.5mg/kg
Experimental
All participants (fasted) received either 2.5mg/kg of STSA-1005 as a single dose or dose-matched placebo.
干预措施: STSA-1005 injection (Drug)
Cohort 2:2.5mg/kg
Experimental
All participants (fasted) received either 2.5mg/kg of STSA-1005 as a single dose or dose-matched placebo.
干预措施: Placebo (Drug)
Cohort 3:5mg/kg
Experimental
All participants (fasted) received either 5 mg/kg of STSA-1005 as a single dose or dose-matched placebo.
干预措施: STSA-1005 injection (Drug)
Cohort 3:5mg/kg
Experimental
All participants (fasted) received either 5 mg/kg of STSA-1005 as a single dose or dose-matched placebo.
干预措施: Placebo (Drug)
Cohort 4:10mg/kg
Experimental
All participants (fasted) received either 10 mg/kg of STSA-1005 as a single dose or dose-matched placebo.
干预措施: STSA-1005 injection (Drug)
Cohort 4:10mg/kg
Experimental
All participants (fasted) received either 10 mg/kg of STSA-1005 as a single dose or dose-matched placebo.
干预措施: Placebo (Drug)
结局指标
主要结局
Incidence of Adverse Events, Serious Adverse Events, Clinically Significant Laboratory Abnormalities, Electrocardiogram Abnormalities, Vital Signs Abnormalities and Physical Examination Abnormalities.
时间窗: Day 1 through Day 57
次要结局
- Maximum plasma concentration (Cmax)(Up to 1344 hours postdose)
- Area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t)(Up to 1344 hours postdose)
- Area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)(Up to 1344 hours postdose)
- Time of maximum concentration (Tmax)(Up to 1344 hours postdose)
- Elimination half-life (t1/2)(Up to 1344 hours postdose)
- Fraction of drug eliminated per unit of time (Kel)(Up to 1344 hours postdose)
- Last measurable concentration (Clast)(Up to 1344 hours postdose)
- Apparent volume of distribution (Vz/F)(Up to 1344 hours postdose)
- Mean residence time (MRT)(Up to 1344 hours postdose)
- The number of subjects with anti-drug antibody (ADA) and neutralizing antibody (NAb)(Up to 1344 hours postdose)
- Clearance (CL)(Up to 1344 hours postdose)
- Change from baseline in numbers of neutrophils and monocytes(Up to 1344 hours postdose)
- Changes of granulocyte macrophage colony-stimulating factor (GM-CSF) receptor occupancy (RO) after the administration compared with the baseline(Up to 1344 hours postdose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy SubjectsHealthy VolunteersNCT05103878Bacainn Therapeutics, Inc.50
Unknown
1 期
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral HRS5685 in Healthy SubjectsHuman Immunodeficiency Virus-1 (HIV-1) InfectionNCT05328583RetroLead (Shanghai) BioPharma Co., Ltd.64
已完成
1 期
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy VolunteersHealthy VolunteerNCT01597947Achaogen, Inc.50
已完成
1 期
A Single Dose Study of SHR4640 in Healthy Male VolunteersGoutNCT03015948Atridia Pty Ltd.40
撤回
1 期
A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as BoosterCOVID-19 PandemicNCT05609045Wuhan Rhegen Biotechnology Co., Ltd.